USA

For MSD, this acquisition is part of a broader strategy to diversify its pipeline before its blockbuster immunotherapy Keytruda loses patent protection.

Avlayah’s approval validates Denali’s blood-brain barrier shuttle technology, which the company now applies across five clinical programs targeting Alzheimer’s disease, Parkinson’s disease, and Sanfilippo syndrome type A, among others.

Gilead will pay USD1.68 billion upfront and commit up to USD500 million in milestone payments to secure gamgertamig (OM336), Ouro’s BCMA/CD3-targeting TCE.

The 460,000-square-foot factory will sit on a 79-acre plot within the Rowen innovation district, near Dacula, Georgia, approximately 35 miles northeast of downtown Atlanta.

Construction is expected to be complete by the third quarter of 2027, at which point the site’s workforce is also set to double.

Wegovy HD became the fourth drug to receive FDA approval through the Commissioner’s National Priority Voucher pilot programme.

This transaction grants Collegium a second branded ADHD medication to complement its existing Jornay PM offering.

Psoriasis is a chronic autoimmune disorder in which skin cells multiply excessively, creating thick, itchy, scaly patches that affect more than 8 million Americans.

GlobalData analysis projects that the global nephrology and urology device market, which includes BPH treatments, will reach almost USD12 billion in 2035, up from around USD8.6 billion in 2024.